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The Wnt/β-catenin signaling pathway controls key aspects of embryonic development and adult tissue homeostasis, including the formation and
maintenance of bone. Recently, mutations in theOSTM1 gene were found to be the cause of severe autosomal recessive osteopetrosis in both the mouse
and humans. This disorder is characterized by increased bone mass resulting from a defect in osteoclast maturation. The possible role of OSTM1 in
signaling of the Wnt/β-catenin “canonical” pathway was investigated in totipotent mouse F9 embryonal teratocarcinoma cells. Overexpression of
OSTM1 in F9 cells increased Wnt3a-responsive β-catenin accumulation and Lef/Tcf-sensitive transcription. Similarly, knockdown of endogenous
OSTM1 attenuated the ability of Wnt3a to stimulate the canonical signaling pathway. An OSTM1 mutant (detected in humans with osteopetrosis) was
expressed in F9 cells and found to inhibit Wnt-stimulated β-catenin stabilization, gene transcription, and primitive endoderm formation. Expression of
this OSTM1 C-terminal deletion mutant attenuated Lef/Tcf-sensitive gene transcription, even when transcription was activated by expression of a
constitutively-active form of β-catenin. However, expression of this OSTM1 C-terminal deletion mutant was unable to alter Lef/Tcf-sensitive gene
transcription when transcription was activated by expression of a β-catenin/Lef chimeric protein. From the standpoint of protein–protein interactions,
expression of wild-type OSTM1 stimulated whereasmutant OSTM1 inhibited, theWnt-dependent association ofβ-catenin and Lef1. On the foundation
of these experiments, we propose that the human mutations in OSTM1 such as the C-terminal deletion mutant studied herein provoke dysregulation of
the canonical Wnt/β-catenin signaling pathway, providing a molecular basis for severe autosomal recessive osteopetrosis.
© 2008 Elsevier Inc. All rights reserved.Keywords: β-catenin; Osteopetrosis; OSTM1; Wnt1. Introduction
The canonicalWnt signaling cascade imposes tight regulation on
the transcriptional co-activator β-catenin through a complex of
proteins including glycogen synthase kinase 3β (GSK3β), Axin,
and the product of the adenomatous polyposis coli gene (APC)
[1–3]. Phosphorylation of β-catenin by protein kinases in this
complex stimulates recognition and destruction of β-catenin by
the proteasome [4], ensuring low intracellular levels of “free”
β-catenin in the absence of pathway activation. TheWnt/β-catenin
pathway is triggered by binding of a Wnt ligand to Frizzled (Fz), a
seven-transmembrane G-protein coupled receptor [5], and sub-⁎ Corresponding author. Tel.: +1 516 367 8385.
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complex through the action of heterotrimeric G-proteins and the
phosphoprotein Dishevelled (Dvl) [6–9]. This allows β-catenin to
accumulate in the cytosol, bind tomembers of the Lef/Tcf family of
transcription factors, and activate transcription of genes necessary
for both growth and differentiation [10]. The Wnt/β-catenin
pathway is required for a plethora of steps in the development of
multicellular organisms and regulation of adult tissue homeostasis
[11,12], including the growth and renewal of bone [13]. Several
distinct steps in the accumulation of bone mass are regulated by
Wnt signaling, including stem cell self-renewal, inhibition of
osteocyte apoptosis, and stimulation of osteoblast differentiation
and proliferation [13]. Defects in Wnt pathway components cause
skeletal abnormalities, e.g., the osteoporosis–pseudoglioma dis-
order associated with mutations in Wnt co-receptor low-density
lipoprotein receptor-related protein 5 (LRP5) [14,15].
Fig. 1. OSTM1 mRNA is expressed in F9 cells. RT-PCR was performed on
cDNA generated from RNA isolated from wild-type F9 cells. Primers specific
for OSTM1 and Cyclophilin Awere utilized in the PCR reaction. PCR products
were separated by electrophoresis on a 1% agarose gel and stained with ethidium
bromide. The lane labeled “No cDNA” shows that the PCR reaction is not
contaminated with exogenous DNA.
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caused by deficiencies in bone resorption, resulting in increased
bone mass. Patients with autosomal recessive osteopetrosis suffer
from frequent fractures, hepatosplenomegaly and bone marrow
obliteration, leading to early mortality unless treated with bone
marrow transplantation [16,17]. Mutations in two human genes,
TCIRG1 and CLCN7 (which encodes the ClC-7 protein), together
are known to cause ∼60% of autosomal recessive osteopetrosis
cases. A spontaneous mouse model of ARO allowed the
identification of a third candidate gene, osteopetrosis associated
transmembrane protein 1 (OSTM1) [18]. Subsequently, several
humanmutations inOSTM1 have been uncovered in ARO patients
[16,17]. OSTM1 is a type I transmembrane protein which localizes
to intracellular vesicles (mainly endosomes and lysosomes) and
homologs have been identified broadly, from humans to Caenor-
habditis elegans and Drosophila melanogaster [18]. Two biologi-
cal roles for OSTM1 have been suggested: serving as a cofactor
necessary for ClC-7 function [19]; and, functioning as an E3
ubiquitin ligase for the heterotrimeric G-protein Gαi3 [20]. AsWnt
signaling and OSTM1 are both intimately involved in bone
remodeling,we explored the hypothesis that OSTM1plays a role in
Wnt/β-catenin signal transduction.Fig. 2. OSTM1 potentiates Wnt/β-catenin signaling. (A) F9 cells transiently
transfected with Fz1, M50 and the indicated amounts of OSTM1 were treated
with Wnt3a for 7 h, then collected and subjected to luciferase assay. ⁎ denotes
Pb0.05 for the difference between wild-type, Wnt3a-treated cells and those
expressing OSTM1 and Wnt3a-treated for the individual doses. The data shown
are mean values (±s.e.) of at least three separate experiments. Lower panel:
Western blot analysis was used to measure the expression of transiently
transfected HA-tagged OSTM1. (B) F9 cells transiently transfected with Fz1 and
either empty vector or OSTM1 were treated with Wnt3a for the indicated lengths
of time. Lysates were collected and treated with concanavalin A to separate
cytosolic from membrane associated β-catenin. Cleared samples were subjected
to SDS-PAGE on an 11% acrylamide gel, transferred to nitrocellulose and
probed with an antibody against β-catenin. The results displayed are from a
single representative experiment. Lower panel: Bands from multiple gels were
quantified by densitometry. ⁎ denotes Pb0.05 for the difference between wild-
type cells and those expressing OSTM1 for the individual time points.2. Materials and methods
2.1. Plasmids and antibodies
An expression vector encoding human OSTM1 was obtained from OriGene
(Rockville, MD). Expression vectors containing Fz1 and M50 were provided by
Dr. Randall Moon (Department of Pharmacology, HHMI, University of
Washington, Seattle, WA). Expression vectors containing SAβ-cat and β-cat/Lef
were provided by Dr. Ken-Ichi Takemaru (Department of Pharmacology, SUNY
Fig. 3. OSTM1 knockdown attenuates Wnt/β-catenin signaling. (A) F9 cells
transiently transfected with siRNA sequences targeting OSTM1 (or a control
sequence) and expression vectors encoding Fz1 and M50 were treated with or
withoutWnt3a for 7 h, then collected and subjected to luciferase assay. ⁎ denotes
Pb0.05 for the difference between cells transfected with the control siRNA and
those transfected with the siRNA targeting mouse OSTM1. (B) Reverse-
transcription PCR analysis was used to measure the effect of siRNA treatment on
OSTM1 mRNA levels. The expression of cyclophilin A was used as a loading
control. (C) F9 cells transiently transfected with siRNA sequences targeting
mouse OSTM1 and expression vectors encoding Fz1, M50 and the indicated
amounts of human OSTM1 were treated with or without Wnt3a for 7 h, then
collected and subjected to luciferase assay. ⁎ denotes Pb0.05 for the difference
between cells transfected with the mouse OSTM1 siRNA and those transfected
with the siRNA targeting mouse OSTM1 and human OSTM1 cDNA.
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provided by Dr. Howard Crawford (Department of Pharmacology, SUNY Stony
Brook, Stony Brook, NY). Expression vectors harboring HA-tagged OSTM1 and
OSTM1ΔCwere provided byDr. Thomas Jentsch (FMP/MDC, Berlin, Germany).
The monoclonal TROMA-1 antibody was generated by the University of Iowa
Developmental Studies Hybridoma Bank (Iowa City, IA). The rabbit antibody
against β-catenin and the mouse antibody against actin were obtained from Sigma
(Saint Louis, MO) and the anti-HA affinity matrix and anti-HA antibody were
obtained from Roche (Indianapolis, IN).
2.2. Cell culture and transfection
Mouse F9 teratocarcinoma cellswere obtained from theATCC (Manassas, VA)
and grown in Dulbecco's modified Eagle's medium supplemented with 15% fetal
bovine serum, penicillin (60 μg/ml) and streptomycin (100 μg/ml) in a humidified
atmosphere chamber supplied with 5% CO2 at 37 °C. Cells were transfected by
using Lipofectamine (Invitrogen, Carlsbad, CA), according to the manufacturer's
suggested protocol. Pre-designed siRNA oligonucleotides targeting OSTM1 were
obtained from Ambion (Austin, TX). The sequences are as follows: Sense:
ccaaaaaauuacuccgaagtt; Antisense: cuucggaguaauuuuuuggtg.
The annealed siRNA sequences were transfected into F9 cells using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to the manufacturer's
suggested protocol. RNA was collected 72 h after transfection and knockdown
efficiency measured by RT-PCR.
2.3. Reverse-transcription polymerase chain reaction
Specific primers for amplification of regions of OSTM1 and Cyclophilin A
were obtained from Operon (Huntsville, AL). The sequences are as follows:
OSTM1: atggctcgggacgcggag, aggcaatttgcgcagttcgcc; CycA: agcactggaga-
gaaaggatttg, cacaatgttcatgccttctttc. RNA was isolated from wild-type F9 cells
using the RNA STAT-60 reagent (Tel-Test, Friendswood, TX) according to the
manufacturer's suggested protocol. The reverse transcription reaction was
performed using the Invitrogen Superscript system according to the manufac-
turer's suggested protocol. Primer sets (0.5 μM) were mixed with dNTPs
(1 mM), F9 cDNA (100 ng), 10X Pfu buffer and Pfu Turbo DNA polymerase
(Stratagene, La Jolla, CA). The PCR reaction was performed using the
GeneAmp PCR System 2400 (Applied Biosystems, Foster City, CA) with the
following protocol: 95 °C, 5 min; (95 °C, 1 min; 60 °C, 1 min; 72 °C, 3 min) 30
cycles; 72 °C, 15 min. Reaction products were resolved electrophoretically upon
1% agarose gels and stained with ethidium bromide.
2.4. Gene transcription assay
F9 cells were seeded into 12-well plates and transiently transfected as described
above. After incubation for 48 h at 37 °C, cells were serum-starved overnight, then
treated with purified Wnt3a (R&D Systems, Minneapolis, MN). Cells were lysed
through addition of diluted Cell Culture Lysis Reagent 5X (Promega, Madison,
WI). Lysates were collected and centrifuged at 15,000 ×g for 5 min. The
supernatantwas directly assayed as described below.A sample (20μl) of lysatewas
added to 100 μl of luciferase assay buffer (20 mM Tricine, pH 7.8, 1.07 mM
MgCO3, 4mMMgSO4, 0.1mMEDTA, 0.27mMcoenzymeA, 0.67mM luciferin,
33.3 mMDTT, 0.66 μMATP) and a luminometer (Berthold Lumat LB 9507) was
used to measure luciferase activity.
2.5. Cytosolic β-catenin assay
In order to separate cytosolic from membrane-associated β-catenin, samples
were treatedwith concanavalinA (ConA). ConA (covalently linked to Sepharose)
was obtained from Amersham Biosciences (Upsala, Sweden). F9 cells were
washed once with PBS and lysed in RIPA buffer (20 mM Tris–HCl, pH 7.4,
150 mM NaCl, 5 mM EDTA, 1% Triton X-100) plus leupeptin (10 μg/mL),
aprotinin (10 μg/mL) and PMSF (200 μM). Lysates were rotated at 4 °C for 20min
and then centrifuged for 25 min at 15,000 rpm. The protein concentration of the
supernatant fractionwas determined and lysates were diluted with RIPA buffer to a
protein content of 2.5 mg/ml. Sixty microliters of Con A-Sepharose was added to
each samplewhich thenwas incubated at 4 °C for 1 hwith rotation. The supernatantwas then removed and the protein concentration determined. The samples were
subjected to SDS-PAGEon 10%acrylamide gels, the separated proteins transferred
to nitrocellulose blots, and the blots probed with the anti-β-catenin antibody.
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F9 cells grown in 24-well plates were fixed in 3% paraformaldehyde, then
washed three times in MSM-PIPES buffer (18 mM MgSO4, 5 mM CaCl2,
40 mM KCl, 24 mM NaCl, 5 mM PIPES, 0.5% Triton X-100, 0.5% NP40).
Cells were incubated at 37 °C for 30 min with the TROMA antibody, washed
with MSM-PIPES, and then incubated at 37 °C for 30 min with an anti-mouse
antibody coupled to Alexa Flour 488 (Invitrogen). Cells were then washed in
blotting buffer (560 mM NaCl, 10 mM KPO4, 0.1% Triton X-100, 0.02% SDS)
and imaged with a Zeiss LSM510 inverted fluorescence microscope.
2.7. Immunoprecipitation
F9 cells grown in 100 mm plates were lysed in a buffer composed of 50 mM
TrisHCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and 0.5% NP-
40. 500 μg protein was incubated with 50 μl of resuspended Anti-HA Affinity
Matrix overnight at 4 °C. The matrix was washed three times in lysis buffer and
the bound proteins were eluted with sample buffer. The samples were subjected
to SDS-PAGE on 10% acrylamide gels, the separated proteins transferred to
nitrocellulose blots, and the blots probed with the appropriate antibodies.3. Results
3.1. OSTM1 mRNA is expressed in F9 cells
We chose to investigate the putative role of OSTM1 in Wnt/
β-catenin signaling in mouse teratocarcinoma cells (F9). These
pluripotent cells have been used as a model system to study
signaling events in early mouse development and can be
differentiated to primitive endoderm (PE) by stimulation with
Wnt3a [6]. The lack of suitable antibodies precluded determina-
tion by Western blotting of OSTM1 protein expression in the
mouse F9 cells. Alternatively, we sought confirmation at the
level of mRNA, using reverse-transcription polymerase chain
reaction (RT-PCR). OSTM1 mRNA was positively detected,
being expressed in these cells (Fig. 1).
3.2. OSTM1 potentiates Wnt/β-catenin signaling
The transcriptional response to Wnt/β-catenin signaling can
be measured through the use of an Lef/Tcf-responsive promoter
driving luciferase expression (M50) [21]. Treatment of wild-
type F9 cells with purified Wnt3a stimulated a ∼10-fold
increase in gene transcription, as measured by luciferase activity
(Fig. 2A). We overexpressed OSTM1 in F9 cells in order to
probe whether or not OSTM1 has a functional impact on Wnt/Fig. 4. OSTM1ΔC mutant attenuates Wnt/β-catenin signaling. (A) F9 cells transientl
OSTM1ΔC were treated with Wnt3a for 7 h, then collected and subjected to the lu
treated cells and those expressing OSTM1ΔC and Wnt3a-treated for the individual d
transiently transfected HA-tagged OSTM1ΔC. (B) F9 cells transiently transfected wi
the indicated lengths of time, then collected and subjected to luciferase assay. (C) F9 c
treated with Wnt3a for the indicated lengths of time. Lysates were collected and tr
catenin. Cleared samples were subjected to SDS-PAGE on an 11% acrylamide gel, t
results displayed are from a single experiment representative of more than three i
densitometry. ⁎ denotes Pb0.05 for the difference between wild-type cells and thos
transfected with Fz1, M50 and the indicated constructs (or treated with Wnt3a for 7
difference between Wnt/β-catenin pathway activated cells and those expressing OST
indicated amounts of SAβ-catenin or wild-type β-catenin were collected and sub
transfected with SAβ-catenin or wild-type β-catenin and an empty vector and thoseβ-catenin signaling. Overexpression of OSTM1 increased the
Wnt3a-induced Lef/Tcf response in a dose-dependent manner
(Fig. 2A). In all conditions, constant levels of DNA were
maintained through the use of an empty vector. The potentiation
of Wnt3a-stimulated activity was more than double in those
cells transfected with the highest amount of expression vector
harboring OSTM1. The basal levels of reporter activation also
were potentiated by overexpression of OSTM1. Cytosolic
accumulation of β-catenin and subsequent nuclear translocation
are required for Wnt-responsive Lef/Tcf-mediated gene tran-
scription [22]. Therefore, we probed the intracellular β-catenin
levels in Wnt3a-treated cells, comparing those cells that were
overexpressing OSTM1 to those transfected with an empty
vector (Fig. 2B). Intracellular levels of β-catenin were low in
unstimulated F9 cells (Fig. 2B; 0 h time points). Upon Wnt3a
stimulation of cells transfected with an empty vector, accumula-
tion of β-catenin was seen within 2 h, remaining constant
through 3 h. In cells expressing OSTM1, basal levels of
intracellular β-catenin were unchanged as compared with the
control condition. However, in cells transfected with OSTM1
and treated with Wnt3a, accumulation of β-catenin occurred
rapidly (within 1 h), and was maintained at an elevated level
past 3 h, compared with cells expressing an empty vector.
3.3. OSTM1 knockdown attenuates Wnt/β-catenin signaling
If OSTM1 acts to potentiateWnt3a stimulation of the canonical
pathway, conventional wisdom would suggest that the absence of
OSTM1 would also impact signaling. To probe this role of
OSTM1 in Wnt/β-catenin signaling, specific siRNA sequences
were utilized to knock down OSTM1 expression in mouse F9
cells. Cells transfectedwith a control (scrambled) siRNA sequence
responded to Wnt3a stimulation with a normal ∼10-fold increase
in Lef/Tcf-mediated gene transcription (Figs. 2A, 3A). In the
absence of Wnt3a, basal levels of gene transcription were
equivalent in control and OSTM1 knockdown conditions
(Fig. 3A). The Lef/Tcf-mediated transcriptional response to
Wnt3a, in sharp contrast, was attenuated by more than 70% in
cells treated with an siRNA targeting mouse OSTM1 (Fig. 3A).
OSTM1 appears to play an essential role in Wnt/β-catenin
signaling in response to Wnt3a. RT-PCR analysis of the levels of
OSTM1mRNA demonstrated that the siRNA reagents effectively
knocked down mouse OSTM1 mRNA (Fig. 3B). Two distinct
siRNA sequences designed by the commercial supplier to targety transfected with Fz1, M50 and either empty vector or the indicated amounts of
ciferase assay. ⁎ denotes Pb0.05 for the difference between wild-type, Wnt3a-
oses. Lower panel: Western blot analysis was used to measure the expression of
th Fz1, M50 and either empty vector or OSTM1ΔC were treated with Wnt3a for
ells transiently transfected with Fz1 and either empty vector or OSTM1ΔC were
eated with concanavalin A to separate cytosolic from membrane-associated β-
ransferred to nitrocellulose and probed with an antibody against β-catenin. The
ndependent tests. Lower panel: Bands from multiple gels were quantified by
e expressing OSTM1ΔC for the individual time points. (D) F9 cells transiently
h) were collected and subjected to luciferase assay. ⁎ denotes Pb0.05 for the
M1ΔC. (E) F9 cells transiently transfected with Fz1, M50, OSTM1ΔC and the
jected to luciferase assay. ⁎ denotes Pb0.05 for the difference between cells
transfected with SAβ-catenin or wild-type β-catenin and OSTM1ΔC.
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either of these siRNAs sharply attenuated the ability of Wnt3a to
activate Lef/Tcf-sensitive transcription (data not shown).A rescue experiment was performed to test the specificity of the
OSTM1knockdown response. As described above, knockdown of
mouse OSTM1 with siRNA sharply attenuated Wnt3a-mediated
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(which is resistant to degradation by the specific siRNAs utilized in
this study due to sequence divergence) in these siRNAknockdown
cells lacking endogenous mouse OSTM1 successfully rescued the
ability of these cells to respond toWnt3a. The rescue of theWnt3a-
induced canonical pathway in OSTM1-depleted cells by over-
expression of human OSTM1 was dose-dependent with regard to
the expression vector harboring OSTM1 (Fig. 3C).
3.4. OSTM1ΔC mutant acts as a dominant negative in
Wnt/β-catenin signaling
Having demonstrated a functional role of OSTM1 in Wnt/β-
catenin canonical signaling we were able to focus on the effects
of a known OSTM1 mutation that causes osteopetrosis in
humans. There are multiple mutations of OSTM1 that cause
autosomal recessive osteopetrosis [18]. We investigated the effect
of a well-known humanOSTM1mutation [19] on Wnt/β-catenin
signaling. The OSTM1 C-terminal deletion mutant (deletion of
the final 72 amino acids; OSTM1ΔC) was constructed and we
tested its ability to modulate Wnt/β-catenin canonical signaling.
Overexpression of OSTM1ΔC was found to attenuate Wnt3a-
induced transcription in a dose-dependent manner (Fig. 4A). In
all conditions, constant levels of DNAwere maintained through
the use of an empty vector. Basal levels of Lef/Tcf-sensitive
transcription were influenced to a lesser extent. Next, a time-
course for Wnt3a-mediated gene transcription was undertaken
(Fig. 4B). Treatment of F9 cells with Wnt3a induced an increaseFig. 5. OSTM1ΔC attenuates Wnt3a-induced PE formation. F9 cells transiently trans
Wnt3a for 4 days. Cells were stained with an antibody against cytokeratin endo A ain Lef/Tcf-sensitive transcription by 4 h, rising sharply at 5
through 8 h. Expression of OSTM1ΔC attenuated the amplitude
of Wnt3a-induced transcriptional response by more than 50%
(Fig. 4B).
To focus on the point at which the OSTM1ΔCmutant impacts
theWnt-induced transcriptional pathway, we measuredβ-catenin
levels in cells expressing OSTM1ΔC or an empty vector and
treated with Wnt3a (Fig. 4C). Wild-type F9 cells treated with
Wnt3a initiated accumulation of cytosolic β-catenin within 1 h,
and reached a peak of β-catenin around 2–3 h. Cells expressing
OSTM1ΔC displayed little change in basal levels of cytosolic β-
catenin. Expression of OSTM1ΔC clearly attenuated the ability
of Wnt3a to induce β-catenin accumulation (Fig. 4C).
The effects of expression of OSTM1ΔC on Lef/Tcf-mediated
transcription were measured in response to activation of the
canonical pathway byWnt3a and downstream elements in order to
determine the epistatic level ofOSTM1ΔCaction onWnt signaling
(Fig. 4D). Expression of OSTM1ΔC inhibited Wnt3a-induced
transcription by more than 50% (Fig. 4A,B,D). Overexpression of
Dvl3 induces Lef/Tcf-mediated gene transcription [23].
OSTM1ΔC expression inhibited Dvl3-stimulated transcriptional
activation by 50% (Fig. 4C). Expression of a constitutively active
β-catenin mutant (lacking four N-terminal phosphorylation sites
necessary for proteasome recognition; SAβ-cat) was utilized to
activate Lef/Tcf gene transcription. Overexpression of OSTM1ΔC
attenuated SAβ-cat-induced transcriptional activation bymore than
70% (Fig. 4D). Expression of a β-catenin/Lef fusion protein (β/
Lef) [24] as well as a constitutively-active Lef mutant (VP16/Lef)fected with OSTM1, OSTM1ΔC or an empty vector were treated with or without
nd imaged by indirect immunofluorescence. PC, phase contrast.
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in the Wnt/β-catenin pathway. In contrast to its ability to attenuate
canonical signaling in response to activation by Wnt3a, over-
expression of Dvl3, and expression of SAβ-catenin, expression of
OSTM1ΔC was unable to attenuate Lef/Tcf-mediated signaling
induced by expression of either of the Lef mutants (Fig. 4D).
To further explore the ability of OSTM1ΔC to inhibit Wnt
signaling, we tested the effects of OSTM1ΔC expression on cells
with increasing expression of SAβ-catenin or wild-type β-catenin
(Fig. 4E). In the absence of expression of SAβ-catenin or wild-
type β-catenin, OSTM1ΔC expression had no obvious effect on
Lef/Tcf-sensitive transcription, when compared with cells trans-
fected with an empty vector. At higher levels of expression of
SAβ-catenin or wild-type β-catenin, however, OSTM1ΔC-
induced inhibition was observed. Expression of OSTM1ΔC
inhibited transcription ∼50%, even at the highest tested levels of
SAβ-catenin or wild-type β-catenin.
3.5. OSTM1ΔC attenuates the ability of Wnt3a to stimulate PE
formation
F9 cells can be induced to form PE in response to Wnt3a [6],
indicated by the expression of PE-specific markers such as
cytokeratin endo A. PE is a cardinal stage in early mouse devel-Fig. 6. OSTM1 regulates β-catenin/Lef1 interaction. F9 cells transiently
transfected with Lef1-HA and either OSTM1, OSTM1ΔC or an empty vector
were treated with or without Wnt3a for 3 h. Cell lysates were collected and
subjected to immunoprecipitation with an anti-HA antibody. The amount of
endogenous β-catenin pulled down under each condition was measured through
Western blot analysis using an anti-β-catenin antibody. Lower panel: Bands from
multiple gels were quantified by densitometry. ⁎ denotesPb0.05 for the difference
between untreated cells and those treated with Wnt3a.opment and can bemeasured using themouse TROMAantibody to
endo A [26]. Indirect immunofluorescence was utilized to detect
expression of cytokeratin endo A in F9 cells treated with Wnt3a
(Fig. 5). Untreated F9 cells do not express cytokeratin endo A, i.e.,
no positive staining by the TROMA antibody. Expression of
OSTM1ΔCblocked the ability of F9 cells to formPE in response to
Wnt3a. In the absence of Wnt3a, overexpression of OSTM1 or
OSTM1ΔC had no effect on TROMA staining. In the presence of
Wnt3a, cells transfected with an empty vector or OSTM1 stained
positive for TROMA, indicating PE formation. Thus, expression of
the OSTM1ΔC mutant blocked the ability of Wnt3a to signal to a
major embryonic response, PE formation.
3.6. OSTM1 regulates β-catenin/Lef1 interaction
The epistasis experiments (Fig. 4D) implicated OSTM1ΔC
action on Wnt/β-catenin signaling, downstream of β-catenin
accumulation, but upstream of β-catenin/Lef1 interaction. We
compared the ability of OSTM1 and OSTM1ΔC to regulate the
Wnt3a-induced binding of β-catenin to Lef1 (Fig. 6). In the
absence of Wnt3a, immunoprecipitated HA-Lef1 was able to pull
down a small amount of endogenous β-catenin. This effect was
unaltered in unstimulated cells expressingOSTM1 orOSTM1ΔC.
β-catenin binding to Lef1 increased in cells treated with Wnt3a
(Fig. 6, compare lanes 1 and 2). The ability of β-catenin to bind
Lef1 was increased in Wnt3a-treated cells expressing OSTM1. In
Wnt3a-treated cells expressing OSTM1ΔC, in sharp contrast, no
detectable binding of β-catenin was observed.
4. Discussion
The Wnt/β-catenin pathway controls key steps in both the
development and maintenance of multicellular organisms [11,12].
Mutations in severalWnt pathway components lead to a number of
human diseases, including cancer [12]. For example, patients with
one defective APC allele present with Familiar Adenomatous
Polyposis (FAP), characterized by the development of colon
polyps which frequently progress to malignant adenocarcinoma
[27,28]. As many as 90% of patients with spontaneous colorectal
cancer are found to have APC loss-of-function mutations [29].
However, alterations in Axin2 and β-catenin have also been
reported in colon cancers with wild-type APC [30,31]. Activating
mutations in β-catenin have been identified in spontaneous
pilomatricomas [32], and inactivating Lef1mutations in sebaceous
tumors [33]. Additionally, Wnt signals modulate bone formation
through regulation of stem cell self-renewal, osteocyte apoptosis
and osteoblast differentiation and proliferation [13]. Mutations in
several Wnt signaling components lead to dramatic bone defects,
including osteoporosis–pseudoglioma in patients with LRP5
defects [14]. In the current work, we focus not on a mutation
that causes cancer, but one that leads to osteopetrosis.
Severe autosomal recessive osteopetrosis is a genetic disorder
caused bymutations in several genes affecting osteoclast function,
leading to fragile bones and increased infection rates [16,17].
Recently, defects in theOSTM1 gene have been found to generate
ARO, both in humans and in the spontaneous grey-lethal mouse
model. While several functions for OSTM1 have been proposed
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to ARO warrant further investigation. As Wnt signaling is
critically important for bone maintenance, in the present study
we tested the hypothesis that OSTM1 regulates Wnt/β-catenin
signaling. We found that OSTM1 overexpression potentiated, and
OSTM1 knockdown suppressed,Wnt3a-mediated responses in F9
cells. Furthermore, we determined the mechanism whereby
OSTM1 regulates Wnt signaling: through modulation of the β-
catenin/Lef1 interaction, a crucial downstream event in Wnt/β-
catenin signal transduction.
In order to assess the effect of OSTM1 overexpression or
suppression on Wnt/β-catenin signaling we utilized a luciferase-
based Lef/Tcf-sensitive reporter construct which can be activated
in response to Wnt3a or transfection with constitutively active
Wnt signaling components [21]. Overexpression of OSTM1
intensifiedWnt signaling in a dose-dependentmanner. In contrast,
knockdown of OSTM1 attenuated Wnt3a-induced gene tran-
scription, an effect which was rescued upon overexpression of
humanOSTM1 cDNA. Intracellular accumulation ofβ-catenin in
response to Wnt3a is a hallmark of the canonical Wnt signaling
pathway [34] and can be used as a reliable marker of Wnt3a
signaling activity. Overexpression of OSTM1 intensified β-
catenin accumulation in response to Wnt3a. This result is
consistent with the transcriptional readout and suggestive of a
positive role for OSTM1 in Wnt/β-catenin signaling.
Importantly, expression of an OSTM1mutant (modeled after a
known ARO human mutation) suppressed Wnt3a-mediated gene
transcription in a time and dose-dependent manner, suggesting a
possible Wnt signaling defect in ARO patients. Similarly,
expression of OSTM1ΔC attenuated β-catenin accumulation in
response toWnt3a. In order to determine the mechanism of action
of OSTM1 in theWnt signal transduction pathway, knowledge of
the epistatic level of OSTM1 was first required. Epistasis
experiments revealed that OSTM1ΔC blocked Wnt/β-catenin
signaling downstream ofβ-catenin accumulation, yet upstream of
the transcriptionally active β-catenin/Lef1 protein complex.
Therefore, we tested the ability of OSTM1 and OSTM1ΔC to
regulate the β-catenin/Lef1 interaction. Overexpression of
OSTM1 intensified, while OSTM1ΔC inhibited, the Wnt3a-
stimulated interaction of β-catenin with Lef1, suggesting that
OSTM1 may function as a mediator of this critical protein
complex. It will be informative to probe the β-catenin/Lef1
interaction in cells from grey-lethal mice or ARO patients with
OSTM1 deficiency.
Finally, expression of OSTM1ΔC was shown to inhibit the
formation of primitive endoderm in response to Wnt3a. This
data clearly indicates that a known human genetic lesion in
OSTM1 can impact cellular differentiation and function. Our
results suggest that mutations in OSTM1 may lead to severe
autosomal recessive osteopetrosis through disruption of Wnt/β-
catenin signaling.
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